Nabi Biopharmaceuticals (NASDAQ:NABI)

CAPS Rating: 4 out of 5

The Company leverage its experience and knowledge in powering the human immune system to develop and market products that target serious medical conditions in the areas of transplantation, infectious disease and hematology/oncology.

Recs

0
Player Avatar HardnoseDotCom (73.45) Submitted: 4/25/2011 1:31:30 PM : Outperform Start Price: $5.56 NABI Score: -70.46

low PEG, strong price uptrend

Report this Post 1 Comment
Member Avatar MegaShort (99.96) Submitted: 3/1/2012 10:43:53 PM
Recs: 0

PEG isn't a very meaningful ratio when both PE and growth are negative.

Featured Broker Partners


Advertisement